Could a simple Finger-Prick replace blood draws for antiphospholipid patients?
NCT ID NCT07570511
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether a finger-stick device (Coaguchek) can accurately measure blood thickness in people with antiphospholipid syndrome who take blood thinners. Currently, these patients need regular blood draws from a vein, which is inconvenient. The study will compare finger-stick results to standard lab tests in 150 adults to see if the simpler method is reliable enough for everyday use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that finger-stick INR tests are reliable for people with antiphospholipid syndrome, making blood monitoring easier and more convenient.
- What could go wrong
- This is an early observational study with no treatment being tested. It may find that finger-stick tests are not accurate enough, so current practice may not change.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Nancy
Vandœuvre-lès-Nancy, 54500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood platelet trends may reveal hidden risk in autoimmune disease
- Immune clues in the blood may foretell heart trouble
- Can a simple blood test tell two forms of a clotting disorder apart?
- New fingerstick test for blood thinner monitoring put to the test
- New MRI study seeks hidden stroke causes in rare blood disorder
- New hope for stroke survivors with rare clotting disorder: rivaroxaban vs warfarin